Recursion Pharmaceuticals Inc’s recently made public that its Chief Executive Officer Gibson Christopher unloaded Company’s shares for reported $0.84 million on Mar 27 ’25. In the deal valued at $6.04 per share,138,574 shares were sold. As a result of this transaction, Gibson Christopher now holds 1,117,450 shares worth roughly $4.44 million.
Then, Gibson Christopher bought 138,574 shares, generating $836,987 in total proceeds.
Before that, Gibson Christopher sold 20,000 shares. Recursion Pharmaceuticals Inc shares valued at $131,600 were divested by the Chief Executive Officer at a price of $6.58 per share. As a result of the transaction, Gibson Christopher now holds 1,256,024 shares, worth roughly $4.99 million.
Morgan Stanley initiated its Recursion Pharmaceuticals Inc [RXRX] rating to an Equal-weight in a research note published on May 22, 2023; the price target was $8. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. KeyBanc Capital Markets began covering RXRX with “an Overweight” recommendation on September 16, 2022. BofA Securities revised its rating on April 18, 2022. It rated RXRX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of RXRX
On Tuesday, Recursion Pharmaceuticals Inc [NASDAQ:RXRX] saw its stock fall -5.48% to $3.97. Over the last five days, the stock has lost -22.08%. Recursion Pharmaceuticals Inc shares have fallen nearly -41.27% since the year began. Nevertheless, the stocks have fallen -55.24% over the past one year. While a 52-week high of $12.36 was reached on 02/18/25, a 52-week low of $3.80 was recorded on 04/07/25. SMA at 50 days reached $7.04, while 200 days put it at $7.03.
Levels Of Support And Resistance For RXRX Stock
The 24-hour chart illustrates a support level at 3.73, which if violated will result in even more drops to 3.49. On the upside, there is a resistance level at 4.35. A further resistance level may holdings at 4.73. The Relative Strength Index (RSI) on the 14-day chart is 25.59, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.59%. Stochastics %K at 8.13% indicates the stock is a buying.
How much short interest is there in Recursion Pharmaceuticals Inc?
A steep rise in short interest was recorded in Recursion Pharmaceuticals Inc stocks on 2025-03-14, growing by 10.97 million shares to a total of 86.42 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 75.45 million shares. There was a rise of 12.69%, which implies that there is a positive sentiment for the stock.
